Know Cancer

forgot password

A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma

Phase 3
18 Years
Not Enrolling
Melanoma, Metastases

Thank you

Trial Information

A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma accounts for approximately 5% of all skin cancers in the United States, but it
accounts for about 75% of all skin cancer deaths. In 2004, the expected prevalence of
melanoma is 627,252, with about 119,178 of these cases being Stage III or IV (metastatic
melanoma). First line treatments for metastatic melanoma, usually IL-2, dacarbazine and/or
temozolomide, are associated with significant toxicities. MDX-010 (anti-CTLA4) antibodies
are designed to keep the immune system running by blocking CTLA-4 from down-regulating T
cell activation. MDX-1379 is made up of two peptides that are pieces of a bigger melanoma
protein (gp100). These peptides bind to HLA-A2 which is then recognized by T cells.

Inclusion Criteria:

- Diagnosed with malignant melanoma

- Measurable unresectable Stage III or IV melanoma

- HLA-A*0201 positive

- Previous treatment with & failure/relapse/inability to tolerate IL-2, dacarbazine
and/or temozolomide

- At least 4 weeks since prior treatment

- Negative pregnancy

- Life expectancy greater than 4 months

- Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1

- Required lab values

- Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV)

Exclusion Criteria:

- Prior malignancies which the patient has not been disease free for over 5 years,
except treated and cured basal or squamous cell skin cancer, superficial bladder
cancer, carcinoma in situ of the cervix, or any other cancer

- Ocular melanoma

- Active, untreated central nervous system (CNS) metastasis

- Prior treatment with MDX-010 (anti-CTLA4) antibody

- Prior treatment with any cancer therapeutic vaccine

- Active autoimmune disease or history of autoimmune disease

- Pregnancy or nursing

- Hypersensitivity to Incomplete Freund's Adjuvant (IFA) (Montanide ISA-51)

- Underlying medical conditions deemed hazardous if treated with study drug

- Concomitant therapy with anti-melanoma drugs, chemotherapies, other investigational
therapies, chronic use of systemic corticosteroids

- Unable to provide informed consent

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone

Outcome Description:

OS was defined as the time from randomization until death from any cause. If a participant did not expire, the subject was censored at the time of last contact (last known alive date). 95% confidence intervals (CI) for median were computed using Brookmeyer and Crowley method.

Outcome Time Frame:

From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)

Safety Issue:


Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb


United States: Food and Drug Administration

Study ID:




Start Date:

September 2004

Completion Date:

October 2009

Related Keywords:

  • Melanoma
  • Metastases
  • melanoma
  • metastatic melanoma
  • skin cancer
  • Melanoma
  • Neoplasm Metastasis



Arizona Cancer Center Tucson, Arizona  85724
Memorial Sloan Kettering Cancer Center New York, New York  10021
USC/Norris Comprehensive Cancer Center Los Angeles, California  90033-0800
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania  15213
Fletcher Allen Health Care Burlington, Vermont  05401
Henry Ford Hospital Detroit, Michigan  48202
Huntsman Cancer Institute Salt Lake City, Utah  84112
James Graham Brown Cancer Center Louisville, Kentucky  40202
Joe Arrington Cancer Research and Treatment Center Lubbock, Texas  79410-1894
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland  21231-2410
Franklin Square Hospital Center Baltimore, Maryland  21237
Hackensack University Medical Center Hackensack, New Jersey  07601
Central Baptist Hospital Lexington, Kentucky  40503
University of Louisville Hospital Louisville, Kentucky  40202
Arlington Cancer Center Arlington, Texas  76012
City of Hope National Medical Center Los Angeles, California  91010
Cancer Centers of the Carolinas Greenville, South Carolina  29605
Mount Sinai Comprehensive Cancer Center Miami Beach, Florida  33140
Memorial Regional Cancer Center Hollywood, Florida  33021
Moores UCSD Cancer Center La Jolla, California  92093-0658
Vanderbilt University Medical Center Nashville, Tennessee  37232-2516
Ellis Fischel Cancer Center Columbia, Missouri  65203
Pacific Shores Medical Group Long Beach, California  90813
Rocky Mountain Cancer Centers Thornton, Colorado  80260
Palm Beach Cancer Institute West Palm Beach, Florida  33401
Center for Cancer Care at Goshen Health System Goshen, Indiana  46526
City of Hope Medical Group Pasadena, California  91105
Mount Sinai Comprehensive Cancer Center at Aventura Aventura, Florida  33180
University of Colorado Health Sciences Center Denver, Colorado  80262
Scripps Cancer Center La Jolla, California  92037
Center for Oncology Research and Treatment Dallas, Texas  75230
Family Cancer Center Collierville, Tennessee  38017
H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida  33612
Dana Farber Cancer Institute Boston, Massachusetts  02115
University of Colorado Hospital Denver, Colorado  80262
Providence Portland Medical Center Portland, Oregon  97213-3635
Mount Sinai Medical Center Miami Beach, Florida  33140
The Cleveland Clinic Foundation Cleveland, Ohio  
University of California, San Diego La Jolla, California  92037-1709
University Medical Center Tucson, Arizona  85724
San Diego Cancer Center Vista, California  92083
Decatur Memorial Hospital Decatur, Illinois  62526
Hematology-Oncology Associates of Northern NJ, PA Morristown, New Jersey  07962
Overlook Oncology Center Summit, New Jersey  07901
The West Clinic Memphis, Tennessee  38120
The Cancer Institute of New Jersey New Brunswick, New Jersey  08901
Cancer Care Specialists of Central IL Decatur, Illinois  62526
Robert Wood Johnson University Hospital New Brunswick, New Jersey  08903
Anschutz Cancer Pavilion Aurora, Colorado  
University of Florida/Jacksonville Faculty Clinic Jacksonville, Florida  32209
Shands Jacksonville Jacksonville, Florida  32209
New Mexico Oncology Hematology Consultants, Ltd. Albuquerque, New Mexico  87109
The Cancer Center at Hackensack University Medical Center Hackensack, New Jersey  07601
Barnes Jewish Hospital St. Louis, Missouri  63110
Cancer Institute Medical Group, Inc Santa Monica, California  90404
M.D. Anderson Cancer Center Orlando Orlando, Florida  32806
University of North Carolina at Chapel Hill Chapel Hill, North Carolina  27599
Hillman Cancer Center Pittsburg, Pennsylvania  15232
La Jolla Hematology and Oncology Medical Group La Jolla, California  92037
The Angeles Clinic and Research Institute Los Angeles, California  90025
North County Oncology Medical Clinical, Inc. Oceanside, California  92056
St. Mary's Medical Center - Northern California Melanoma Center San Francisco, California  94109
Yale University School of Medicine - Oncology Outpatient Clinic New Haven, Connecticut  06520
Jackson Memorial Hospital & Clinics Miami, Florida  33136
University of Miami Hospital & Clinics Miami, Florida  33136
Emory University Hospital-Winship Cancer Institute Atlanta, Georgia  30322
Cardinal Bernardin Cancer Center, Loyola Unv. Med. Ctr. Maywood, Illinois  60153
Indiana Oncology Hematology South Indianapolis, Indiana  46237
American Health Network of IN, LLC Indianapolis, Indiana  46237
Indiana Oncology Hematology Consultants North Indianapolis, Indiana  46202
Indiana Oncology Hematology Consutants of Noblesville Noblesville, Indiana  46060
Norton Hospital Louisville, Kentucky  40202
Brigham and Womens Hospital Boston, Massachusetts  02115
Beth Isreal Dec Medical Center Boston, Massachusetts  02115
Henry Ford Medical Center Dearborn, Michigan  48126
Henry Ford Medical Center- West Bloomfield West Bloomfield, Michigan  48322
Humphrey Cancer Center Coon Rapids, Minnesota  55433
Hubert H Humphrey Cancer Center Robbinsdale, Minnesota  55422
Family Cancer Center Olive Branch, Mississippi  38654
St. Joseph Oncology, Inc St. Joseph, Missouri  64507
Washington Unv. School of Med./ Siteman Cancer Center St. Louis, Missouri  63110
Hematology-Oncology Associates of CNY East Syracuse, New York  13057
Columbia University Medical Center, Irving Center for Clinical Research New York, New York  10032
The Christ Hospital Cancer Center Cincinnati, Ohio  45219
The Oregon Clinical Portland, Oregon  97213
Penn State Milton S. Hershey Medical Center Hershey, Pennsylvania  17033
Thomas Jefferson University Hosptital Philadelphia, Pennsylvania  19107
Hillman Cancer Research Pavilion Pittsburgh, Pennsylvania  15213